أعاد Arab Union of the Manufacturers of Pharmaceuticals and Medical Appliances (AUPAM) نشر هذا
The FDA has reached a significant milestone by approving 60 biosimilars! As of October 2024, several of these approvals were granted without the need for new clinical efficacy studies, relying instead on analytical data demonstrating similarity. Approximately 10-15 of these biosimilars were approved through this pathway. The EMA has also approved a few biosimilars under similar criteria. However, in our region, there remains considerable resistance to adopting policies and strategies that would enhance patient access to these essential, life-saving medicines.
BREAKING NEWS: 🎉 The FDA has now approved 60 #biosimilars, broadening treatment options for conditions like #diabetes, #arthritis, and #ibd. As healthcare providers, it's crucial to stay informed about these safe and effective alternatives to reference products. Search the FDA's Purple Book to see if there are approved biosimilars that could benefit the conditions you treat and to learn more about biosimilars: https://bit.ly/3WZioLS